Search

Your search keyword '"R E Denisov"' showing total 4 results
Start Over Author "R E Denisov"
4 results on '"R E Denisov"'

1. Efficiency of the ALL-MB-2002 protocol in children with acute lymphoblastic leukemia

Author

Yu V Rumyantseva, A I Karachunsky, O V Aleinikova, L G Fechina, A V Shamardina, D V Litvinov, N I Ponomareva, E G Boichenko, S A Dudkin, O V Streneva, K L Kondratchik, E G Mansurova, L M Minkina, E S Lapotentova, E V Inyushkina, N B Yudina, G P Pavlova, E V Zhukovskaya, O P Khlebnikova, S N Lagoiko, E V Basharova, R E Denisov, V D Zlobina, E S Banshchikova, K S Aslanyan, E V Kondakova, E V Tselousova, N V Myakova, T V Turobova, O V Ryskal, N F Chipsanova, S R Varfolomeyeva, and A G Rumyantsev

Subjects
acute lymphoblastic leukemia, children, efficiency of therapy, Medicine
Abstract

Aim. To evaluate the efficiency of the original ALL-MB-2002 protocol within the multicenter study of treatment of acute lymphoblastic leukemia (ALL) in children. Subjects and methods. A total of 1873 primary patients with ALL aged 1 to 18 years, of whom 1544 patients were enrolled in this study, were notified at 36 clinics of Russia and Belarus from April 15, 2002, to January 1, 2008. Results. With the median observation of 4.12 years, 7-year event-free survival (EFS) was 73±13%; overall survival (OS) 78±2%; relapse-free survival 82±1%. The rates of EFS and OS were equal and amounted to 76±2 and 80±2% in the standard-risk group (SRG) and intermediate-risk group (ImRG), respectively. In the high-risk group (HRG) patients, EFS and OS were as high as 30±6 and 37±6%, respectively. The frequency of relapses with central nervous system lesion was as much as 4.7% in all the patients, 6-year cumulative risk for isolated neurorecurrences being 2.5% in the SRG patients. Adolescents, patients with the baseline leukocytosis (more than 100109/l), and those with a splenic size of over 4 cm or more from the costal arch margin had substantially worse survival rates. A poor early response to therapy (on induction days 8 and 15) was also associated with its lower efficiency. Conclusion. Despite a considerable rise in the number of centers and a slight increase in the intensity of therapy, the results of the new ALL-MB-2002 protocol are as minimum equivalents obtained in the use of the previous ALL-MB-91 protocol. A significant improvement in the overall results of therapy and a reduction in the cumulative risk for isolated neurorecurrences were noted in the ImRG patients.

Published
2010

2. Prognostic factors of children’s acute lymphoblastic leukemia therapy in Moscow—Berlin protocols

Author

J. V. Roumiantseva, A. I. Karachunsky, O. V. Aleinikova, L. G. Fechina, A. V. Schamardina, D. V. Litvinov, N. I. Ponomareva, E. G. Boichenko, L. V. Sidorenko, S. A. Dudkin, O. V. Streneva, K. L. Kondratchik, E. G. Mansurova, L. M. Minkina, E. S. Lapotentova, E. V. Inuschkina, N. B. Yudina, G. P. Pavlova, E. V. Zhukovskaya, O. P. Chlebnikova, S. N. Lagoiko, E. V. Bascharova, R. E. Denisov, V. D. Zlobina, E. S. Banschikova, K. S. Aslanyan, E. V. Kondakova, E. V. Celousova, N. V. Myakova, T. V. Turobova, O. V. Riskal, N. F. Chipsanova, S. R. Varfolomeeva, and A. G. Rumiantsev

Subjects
acute lymphoblastic leukemia (all), children, chemotherapy, all-mb 2002, prognostic factors, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Проанализирована значимость прогностических факторов эффективности терапии у детей с острым лимфобластным лейкозом (ОЛЛ), получающих терапию по протоколу ALL-MB-2002, в зависимости от группы риска. В исследование были включены 1544 первичных больных ОЛЛ в возрасте от 1 года до 18 лет, получавших лечение в 36 клиниках России и Беларуси в период с 15 апреля 2002 г. до 1 января 2008 г. Из 1544 больных, включенных в анализ, пациенты группы стандартного риска (SRG) составили 69,2 %, промежуточного риска (ImRG) — 24,5 % и 6,3 % пациентов были отнесены к группе высокого риска. Анализ, проведенный у пациентов SRG, продемонстрировал резкие различия в выживаемости между отдельными подгруппами больных. Выявлены достоверные различия в показателях выживаемости пациентов в зависимости от возраста (старше и младше 10 лет), инициального лейкоцитоза (более и менее 30 × 10 9 /л), инициального пальпаторного увеличения селезенки (более и менее 4 см из-под края реберной дуги) и параметров раннего ответа на терапию (8-й и 15-й день). При ретроспективном определении больных, относящихся к SRG, с использованием новых критериев (инициальный лейкоцитоз

Published
2022

3. [Specialized outpatient care for patients with initial forms of lower limb chronic venous insufficiency]

Author

E P, Burleva and R E, Denisov

Subjects
Adult, Male, Time Factors, Severity of Illness Index, Treatment Outcome, Fibrinolytic Agents, Venous Insufficiency, Chronic Disease, Outpatients, Ambulatory Care, Humans, Female, Saphenous Vein, Vascular Surgical Procedures, Follow-Up Studies, Retrospective Studies, Ultrasonography
Abstract

Authors present 7-year follow up of 567 patients with initial forms of chronic venous insufficiency (CVI) of lower extremities (442 patients with C-1 class and 125 patients with C-2 class). The analysis of individual clinical and ultrasonic data has shown wide variability and the lack of specificity in CVI symptomatology. Ultrasonic investigation revealed veno-venous reflux in 74.6% of patients with C-1 class. Complex outpatient care adhered the principles of minimal invasiveness and radicality, along with individual approach to surgical correction and drug therapy. Early (within 3 weeks) and late (3 and 12 months) outcomes were assessed, including trends in CVI subjective symptoms and objective evaluation of changes in superficial venous system. One year later full clinical and esthetic effect was achieved in 91.4% of C-1 class patients and in 75.8% of C-2 class patients.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results